Suppr超能文献

相似文献

1
Specific domains of nucleolin interact with Hdm2 and antagonize Hdm2-mediated p53 ubiquitination.
FEBS J. 2012 Feb;279(3):370-83. doi: 10.1111/j.1742-4658.2011.08430.x. Epub 2011 Dec 19.
2
Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.
Oncogene. 2006 Nov 23;25(55):7274-88. doi: 10.1038/sj.onc.1209714. Epub 2006 Jun 5.
4
p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Protein Sci. 2018 May;27(5):976-986. doi: 10.1002/pro.3405. Epub 2018 Mar 25.
5
Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26.
Nucleic Acids Res. 2010 Oct;38(19):6544-54. doi: 10.1093/nar/gkq536. Epub 2010 Jun 11.
6
The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids.
FEBS Lett. 2003 Nov 6;554(1-2):73-6. doi: 10.1016/s0014-5793(03)01108-6.
8
Ubiquitination of HEXIM1 by HDM2.
Cell Cycle. 2009 Jul 15;8(14):2247-54. doi: 10.4161/cc.8.14.9015.
9
Hdm2 disrupts HdmX-mediated nuclear export of p53 by sequestering it in nucleus.
Exp Cell Res. 2024 Aug 15;441(2):114185. doi: 10.1016/j.yexcr.2024.114185. Epub 2024 Jul 26.

引用本文的文献

1
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation.
Biomark Res. 2025 Aug 27;13(1):111. doi: 10.1186/s40364-025-00826-7.
3
Insights Into Mitochondrial Dynamics in Chlamydial Infection.
Front Cell Infect Microbiol. 2022 Mar 7;12:835181. doi: 10.3389/fcimb.2022.835181. eCollection 2022.
4
Targeting the oncogenic TBX3:nucleolin complex to treat multiple sarcoma subtypes.
Am J Cancer Res. 2021 Nov 15;11(11):5680-5700. eCollection 2021.
5
Nucleolin Rescues TDP-43 Toxicity in Yeast and Human Cell Models.
Front Cell Neurosci. 2021 Apr 12;15:625665. doi: 10.3389/fncel.2021.625665. eCollection 2021.
6
The nucleolus, an ally, and an enemy of cancer cells.
Histochem Cell Biol. 2018 Dec;150(6):607-629. doi: 10.1007/s00418-018-1706-5. Epub 2018 Aug 13.
7
Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer.
Cell Death Dis. 2018 Jan 19;9(2):47. doi: 10.1038/s41419-017-0067-7.
8
Nucleolin phosphorylation regulates PARN deadenylase activity during cellular stress response.
RNA Biol. 2018 Feb 1;15(2):251-260. doi: 10.1080/15476286.2017.1408764. Epub 2017 Dec 15.
10
Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.
Oncotarget. 2016 Oct 4;7(40):65320-65334. doi: 10.18632/oncotarget.11323.

本文引用的文献

1
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
Annu Rev Pharmacol Toxicol. 2009;49:223-41. doi: 10.1146/annurev.pharmtox.48.113006.094723.
2
Putting a finger on growth surveillance: insight into MDM2 zinc finger-ribosomal protein interactions.
Cell Cycle. 2007 Feb 15;6(4):434-7. doi: 10.4161/cc.6.4.3861. Epub 2007 Feb 18.
3
Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA.
Blood. 2007 Apr 1;109(7):3069-75. doi: 10.1182/blood-2006-08-043257.
4
MDM2 inhibitors for cancer therapy.
Trends Mol Med. 2007 Jan;13(1):23-31. doi: 10.1016/j.molmed.2006.11.002. Epub 2006 Nov 28.
5
MDMX regulation of p53 response to ribosomal stress.
EMBO J. 2006 Nov 29;25(23):5614-25. doi: 10.1038/sj.emboj.7601424. Epub 2006 Nov 16.
6
Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization.
Oncogene. 2006 Nov 23;25(55):7274-88. doi: 10.1038/sj.onc.1209714. Epub 2006 Jun 5.
7
Nucleolin is a histone chaperone with FACT-like activity and assists remodeling of nucleosomes.
EMBO J. 2006 Apr 19;25(8):1669-79. doi: 10.1038/sj.emboj.7601046. Epub 2006 Apr 6.
8
Strategies for therapeutic targeting of the p53 pathway in cancer.
Cell Death Differ. 2006 Jun;13(6):921-6. doi: 10.1038/sj.cdd.4401921.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验